Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at the University of Missouri have successfully used click chemistry to deliver radiopharmaceuticals specifically to tumors in large dogs with bone cancer, increasing effectiveness and minimizing circulation. This breakthrough could pave the way for click chemistry-based treatments for humans with cancer in the future.
Assistant Professor Nourridine Siewe developed a new mathematical model to assess different approaches for treating metastatic cancer. The model evaluates the interactions among immune cells and cancer, helping clinicians decide on the best treatment strategies.
Researchers uncover critical shape-change in cereblon protein that CELMoD drugs must cause to work effectively. The finding enables the development of more effective cancer-fighting treatments.
A study by CeMM researchers and the University of Dundee identifies mutations in E3 ligases that mediate resistances in cell cultures, but also finds that these mutations can be targeted by chemically modified degraders. This understanding has clinical relevance and enables further improvement of cancer therapy drugs.
A recent study found worsening disparities in cancer drug trial participant diversity from 2000 to 2018, highlighting systemic biases and unequal access to new treatments. The findings underscore the need for increased diversity in phase 1 clinical trials to ensure equitable access to life-saving treatments.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers have designed DNA-based transporters that can deliver precise concentrations of drugs, potentially improving cancer treatment. These nanotransporters can also be programmed to prolong the effect of a drug and minimize its dosage, reducing side effects.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
Researchers mapped the detailed neural pathway of defensive responses from the gut to the brain in mice after detecting germs. The study could lead to better anti-nausea medications for cancer patients undergoing chemotherapy.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers have developed a drug compound that stops cancer cell growth in mice with little effect on normal healthy cells, making it potentially nontoxic for patients. The therapy targets the epidermal growth factor receptor gene, which is overexpressed in about half of all triple-negative breast cancer cases.
A new Northwestern Medicine study identifies common and rare gene mutations that impact radiation resistance and sensitivity. This information will allow clinicians to better calibrate radiation doses based on genetic mutations, improving treatment efficacy while reducing toxicity.
Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
A novel polysorbate-based formulation enhances carboplatin's therapeutic response in lymph nodes, amplifying antitumor effects and increasing drug penetration.
Researchers developed a new machine-learning approach to classify macrophages, which are key immune cells involved in pro- or anti-inflammatory responses. This technology could be used as a diagnosis tool or to highlight the role of specific cell types in disease environments.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
A new potential antitumor drug, TRIP, causes rapid protein aggregation, hyperactivating the unfolded protein response and leading to programmed cell death in ovarian cancer cells. The Fe-S cluster biogenesis factor NUBP2 is identified as the probable starting point for the cellular processes triggered by TRIP.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
Researchers developed an AI model that analyzes immune cells to predict which skin cancer patients will benefit from treatments activating the immune system. The study found that patients with more immune cells recognizing skin cancer had better treatment outcomes.
A recent study found that cancer biomarker data is biased towards European populations, potentially misclassifying patients of Asian or African descent. The researchers propose a computational approach to correct this bias, which could have significant implications for treatment selection.
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Scientists from NTU Singapore have discovered that telomeres are stacked in columns like a spring, leaving DNA exposed to damage. This finding could improve understanding of how humans age and develop cancer, with potential treatments for diseases caused by dysfunctional telomeres.
Recent media releases from UK government agencies and NHS organizations lack objectivity and provide unbalanced information on prescription-only medicines. The Drug and Therapeutics Bulletin expresses concerns over the use of hyperbolic language and omission of key information about potential harms and benefits.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.
Researchers at UMC Utrecht will investigate how intestinal microbiota impacts cancer immunotherapy and therapy side effects. The project aims to develop microbiota-targeted therapies to improve ICI treatment effectiveness and reduce severe inflammation.
Researchers at Nagoya University have identified new agents involved in DNA damage tolerance pathways, including RFWD3, which may contribute to anticancer treatment. The study's findings suggest that inhibiting these pathways could sensitize cancer cells to conventional chemotherapeutic agents.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
Cancer cells become resistant to chemotherapies by slowing down DNA replication forks, allowing them to avoid collisions with chemotherapy drugs. A kinase called DNA-PKcs acts as a sensor when a fork is stressed and promotes slowing of the fork and chemo-resistance.
The new SIO-ASCO guideline recommends the use of acupuncture, massage therapy, and other integrative therapies for managing breast cancer-related joint pain, general cancer pain, and chemotherapy-induced peripheral neuropathy. The guidelines also acknowledge areas that need further research to support their recommendations.
Researchers discovered that autophagy facilitates the elimination of cancer cells via cell competition, highlighting its potential as a target for cancer prevention and treatment. The study sheds light on the role of autophagy in maintaining tissue homeostasis and opening avenues for novel anti-cancer therapeutics.
Researchers create a new, non-invasive wearable device that can measure tumor size changes in real-time. The 'Flexible Autonomous Sensor measuring Tumors' (FAST) device provides continuous monitoring and accurate results, offering a promising approach to cancer treatment.
A new wearable device called FAST can measure tumor size changes to the hundredth of a millimeter, providing a fast, accurate, and inexpensive way to test cancer drugs. This technology represents a significant advance in cancer treatment, offering continuous monitoring, flexibility, and non-invasiveness.
Researchers found that 12% of cancer survivors lived in poverty, experiencing negative effects on physical and mental health. Financial burden of cancer care persists years after diagnosis, leading to poor health outcomes and increased mortality.
Researchers at University of California - San Francisco have developed a new therapy that overcomes cancer cell barriers and marks them for destruction by the immune system. By pulling mutated KRAS protein to the surface, the drug acts as an “eat me” flag, allowing immunotherapy to eliminate all cells bearing this flag.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
Researchers found that a specific sequence of drugs can reduce overall costs and improve the value of care for patients with metastatic breast cancer, while minimizing side effects. The study's results suggest that treatment sequencing approaches that minimize costs early may improve the value of care.
Scientists discover that methotrexate causes oxidative damage to the cerebrospinal fluid and choroid plexus, leading to cognitive impairment. Adding antioxidants to the CSF may protect against this damage, offering a potential treatment for 'chemo brain'. Researchers are exploring other chemotherapy drugs and testing antioxidant treatm...
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.
A new combination immunotherapy regimen shows remarkable activity in metastatic colorectal cancer patients without liver metastases, achieving a response rate of 40% and median overall survival exceeding 20 months. The study's findings confirm the importance of the tumor microenvironment in shaping the response to immunotherapy.
Bladder cancer researchers discovered a subset of CD8 T cells that adapts to tumor evasion strategies, offering a strategy to reduce tumor cells' ability to fight them off. The study also identified potential ways to make immunotherapy more effective against this deadly cancer by targeting the HLA-E/NKG2A axis.
Long-term opioid use after lung cancer surgery is associated with a 40% heightened death risk within two years, according to research. The study found that male sex, older age, and chemotherapy treatment are among the factors linked to long-term opioid use.
Researchers found that starting pembrolizumab before surgery significantly improves the outlook for patients with stage III-IV melanoma. The study showed a 42% lower event rate in patients receiving neoadjuvant therapy compared to those receiving adjuvant therapy.
A systematic review and meta-analysis of observational studies found a moderate association between antipsychotic use and an increased risk of breast cancer, estimated at over 30%. The study highlights the importance of risk-benefit assessment of antipsychotic prescription in high-risk patients.
A recent study published in Frontiers in Pediatrics suggests that modern immunotherapies, such as CAR-T cell therapy, could replace traditional stem cell transplantation for high-risk ALL patients. The review also discusses the importance of reducing long-term side effects, including organ damage and secondary cancers.
Researchers conducted a study on administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer and found no increased rates of complications during and after surgery. The findings are encouraging for patients who have not previously received treatment for their oral cavity cancer, suggesting that complication rat...
Breast cancer recurrence and metastatic spread remain a significant challenge, with researchers identifying a metabolic signature that can predict patient outcomes. The signature could be used to develop new therapies targeting cancer metabolism.
A Saint Louis University researcher has identified a potential treatment for 'chemo-brain', a debilitating side effect of chemotherapy that affects patients' quality of life. The treatment targets the molecular events underlying this deficit and repurposes an already-approved FDA drug to reduce cognitive impairment.
A large Nordic study found that children born after frozen-thawed embryo transfer had a higher risk of cancer than those conceived naturally or through fresh embryo transfer. The most common types of cancer seen were leukemia and central nervous system tumors.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.